Prof. Raanan Berger is the Cancer Center director at the Sheba Medical Center. His MD and PhD degrees are from Tel Aviv University and he was a postdoctoral fellow at the Dana Farber Cancer Institute at Harvard Medical School. On 2006 he established the Oncology Clinical Research Center at Sheba, which is the largest center for all-phase oncology clinical trials in Israel.

The first Israeli oncological Early Phase Trial unit was created by Prof. Berger in 2009 and was dedicated to clinical developing of new oncological drugs and treatments. The unit performances and achievements led to the establishment of other collaborations with major pharmaceuticals companies (e.g. Bristol Myers Squibb (BMS), Roche, AstraZeneca and others) aiming to execute first in-human early phase trials with their oncological pipelines.

Academically, Raanan is a Professor of Oncology in the Faculty of Medicine at Tel Aviv University and on his list of publications more than 90 peer reviewed publications.

Prof Berger is an entrepreneur who joined the 8400 network leadership program on 2020. He is active on the advisory boards of a list of biotech startup companies including : Oncohost, Pangea,
Curesponse, Nixio, Idea-Biomedicals, Belong, Polypid and serving as the CMO of Aummune.

Promote personalized cancer medicine and biomarkers driven clinical trials